Mimedx Group, Inc. cash flow statement
In fiscal 2025, Mimedx Group, Inc.'s operations generated $74.0m of cash; it spent $0 on capital projects, leaving free cash flow of $74.0m.
Cash flow statement
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −8 | −7 | 24 | 63 | 36 | −39 | −30 | −2 | −18 | 27 | 66 | 74 | 21 |
| Depreciation and amortisation | 0 | 0 | 3 | 4 | 6 | 7 | 6 | 4 | 3 | 3 | 6 | 15 | 15 |
| Stock-based pay | 1 | 2 | 18 | 21 | 15 | 12 | 15 | 14 | 11 | 17 | 17 | 16 | 5 |
| Capital spending | — | — | — | — | — | — | — | 3 | 2 | 2 | 0 | 0 | 0 |
| Free cash flow | — | — | — | — | — | — | — | −5 | −19 | 25 | 66 | 74 | 21 |
| Free cash flow after stock pay | — | — | — | — | — | — | — | −19 | −31 | 8 | 49 | 58 | 16 |
| Share buybacks | — | — | 10 | 68 | 8 | 0 | 1 | 0 | 0 | 10 | 0 | 0 | — |
| Shares issued | 3 | 0 | — | — | — | — | — | — | — | — | — | — | — |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 19 | 5 | 14 | 29 | 25 | 2 | −10 | 4 |
| Depreciation and amortisation | 4 | 1 | 1 | 1 | 13 | 1 | 0 | 0 |
| Stock-based pay | 5 | 4 | 5 | 5 | 2 | −2 | 1 | 3 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | 19 | 5 | 14 | 29 | 25 | 2 | −10 | 4 |
| Free cash flow after stock pay | 14 | 1 | 10 | 24 | 22 | 4 | −11 | 1 |
Compare with peers
- Organogenesis Holdings Inc. cash flow
- UFP Technologies Inc cash flow
- Orasure Technologies Inc cash flow
- Embecta Corp. cash flow
- ICU Medical Inc cash flow
Head to head: MDXG vs ORGOMDXG vs UFPTMDXG vs OSUR
More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies